专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07835783B1 Magnetic resonance imaging methods and apparatus for time-series motion tracking with inversion recovery compensation 有权
标题翻译：用于具有反转恢复补偿的时间序列运动跟踪的磁共振成像方法和装置
公开(公告)号：US07835783B1
公开(公告)日：2010-11-16
申请号：US10421535
申请日：2003-04-21
申请人： Anthony H. Aletras
发明人： Anthony H. Aletras
IPC分类号： A61B5/05
CPC分类号： G01R33/56333
摘要： Image contributions produced by an untagged specimen magnetization component in magnetic resonance imaging are controlled by applying one or more radiofrequency (RF) pulses that invert at least a portion of the untagged specimen magnetization. In an example, a specimen is tagged with a spatially modulated magnetization that is used to produce an image signal that includes a contribution associated with the tagged magnetization and an untagged magnetization. The untagged magnetization is substantially along an axial direction defined by an applied axial magnetic field. The untagged magnetization increases in magnitude because of so-called T1 relaxation. A contribution to the image signal increases for a predetermined time or to a predetermined magnitude, and a 180-degree pulse is applied to invert at least a portion of the untagged magnetization. The untagged magnetization is then antiparallel with respect to the applied axial magnetic field. Additional inversion recovery causes the untagged magnetization to increase from a negative value to zero and then becomes positive. As a result, signal contributions associated with the untagged magnetization are reduced. Additional 180-degree pulses can be applied whenever the untagged magnetization becomes larger than a predetermined value so that image contrast can be maintained. When the tagged magnetization decreases to a predetermined level, an initial specimen magnetization is reestablished for subsequent imaging.
摘要翻译：通过应用一个或多个射频（RF）脉冲来控制在磁共振成像中由未标记的样本磁化分量产生的图像贡献，其反转至少一部分未标记的样本磁化。在一个示例中，样本被标记有空间调制的磁化，其用于产生包括与标记的磁化和未标记磁化相关联的贡献的图像信号。未标记的磁化基本上沿着由施加的轴向磁场限定的轴向方向。由于所谓的T1弛豫，未标记的磁化强度增加。对图像信号的贡献在预定时间或预定幅度增加，并且施加180度脉冲以反转至少一部分未标记磁化。然后，无标记磁化相对于施加的轴向磁场反平行。额外的反转恢复使得未标记的磁化从负值增加到零然后变为正。结果，与未标记磁化相关联的信号贡献减小。每当无标记磁化变得大于预定值时，可以施加额外的180度脉冲，从而可以保持图像对比度。当标记的磁化强度降低到预定水平时，重新建立初始样品磁化强度，用于随后的成像。

32. 发明授权

US07829102B2 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines 失效
标题翻译：减毒，人 - 牛嵌合呼吸道合胞病毒疫苗的生产
公开(公告)号：US07829102B2
公开(公告)日：2010-11-09
申请号：US11097946
申请日：2005-03-31
申请人： Ursula Buchholz , Peter L. Collins , Brian R. Murphy , Stephen S. Whitehead , Christine D. Krempl
发明人： Ursula Buchholz , Peter L. Collins , Brian R. Murphy , Stephen S. Whitehead , Christine D. Krempl
IPC分类号： A61K39/155
CPC分类号： C12N7/00 , A61K39/00 , A61K39/12 , A61K39/155 , A61K2039/5254 , A61K2039/5256 , A61K2039/544 , C07K14/005 , C07K2319/00 , C12N15/86 , C12N2760/18522 , C12N2760/18534 , C12N2760/18543 , C12N2760/18561 , C12N2840/203
摘要： Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete “background” RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome.
摘要翻译：嵌合人 - 牛呼吸道合胞病毒（RSV）在人类和其他哺乳动物中具有感染性和减毒性，并且可用于引发抗RSV免疫应答的疫苗制剂中。还提供了分离的多核苷酸分子和掺入嵌合RSV基因组或抗原组的载体，其包括部分或完整的人或牛RSV“背景”基因组或与一个或多个异源基因或基因组片段不同的RSV菌株。本发明的嵌合人类牛RSV包括部分或完整的“背景”RSV基因组或在与一个或多个异源基因或基因组片段组合的人或牛RSV病毒株或亚组病毒之后衍生或构图的部分或完整的“背景” 的不同RSV株或亚组病毒形成人 - 牛嵌合RSV基因组或抗原组。

33. 发明授权

US07825126B2 Purine derivatives as A3 and A1 adenosine receptor agonists 失效
标题翻译：嘌呤衍生物作为A3和A1腺苷受体激动剂
公开(公告)号：US07825126B2
公开(公告)日：2010-11-02
申请号：US11574779
申请日：2005-09-02
申请人： Kenneth A. Jacobson , Bhalchandra V. Joshi , Susanna Tchilibon
发明人： Kenneth A. Jacobson , Bhalchandra V. Joshi , Susanna Tchilibon
IPC分类号： C07D473/40 , C07D473/34 , C07D473/18 , A61K31/52 , A61K31/522 , A61P9/02 , C07D473/36 , C07D317/70 , C07D317/28
CPC分类号： C07D473/00
摘要： Disclosed are (N)-methanocarba adenine nucleosides of the formula: as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.
摘要翻译：公开了下式的（N） - 甲氰胺腺嘌呤核苷：作为高效的A3腺苷受体激动剂，包含这种核苷的药物组合物，以及这些核苷的使用方法，其中R1-R6如说明书中所定义。这些核苷被考虑用于治疗许多疾病，例如炎症，心脏缺血，中风，哮喘，糖尿病和心律失常。本发明还提供了作为用于心脏保护的A1和A3腺苷受体的激动剂的化合物。

34. 发明授权

US07824681B2 Human monoclonal antibodies that specifically bind IGF-II 有权
标题翻译：特异性结合IGF-II的人单克隆抗体
公开(公告)号：US07824681B2
公开(公告)日：2010-11-02
申请号：US12063749
申请日：2006-08-15
申请人： Dimiter S. Dimitrov , Yang Feng
发明人： Dimiter S. Dimitrov , Yang Feng
IPC分类号： A61K39/395
CPC分类号： G01N33/57484 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N2333/65
摘要： Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth factor receptor. Nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and isolated host cells that express the nucleic acids are also disclosed. The antibodies can be used to detect human IGF-II in a sample. Methods of diagnosing a tumor are disclosed herein that utilize these antibodies. Methods of treating a subject with a tumor are also disclosed.
摘要翻译：本文公开了分离的单克隆抗体，其特异性结合胰岛素样生长因子II（IGF-II），平衡解离常数（Kd）为1nM或更低，其中所述抗体以平衡解离常数（Kd）结合IGF-I，为1mM以上。抗体抑制胰岛素样生长因子受体的磷酸化。还公开了编码这些抗体的核酸，包括这些核酸的表达载体和表达核酸的分离的宿主细胞。该抗体可用于检测样品中的人IGF-II。本文公开了利用这些抗体的诊断肿瘤的方法。还公开了用肿瘤治疗受试者的方法。

35. 发明授权

US07820174B2 T cell receptors and related materials and methods of use 有权
标题翻译： T细胞受体及相关材料及使用方法
公开(公告)号：US07820174B2
公开(公告)日：2010-10-26
申请号：US12196833
申请日：2008-08-22
申请人： Qiong J. Wang , Kenichi Hanada , James C. Yang
发明人： Qiong J. Wang , Kenichi Hanada , James C. Yang
IPC分类号： A61K38/17
CPC分类号： C07K14/70503 , A61K35/17 , A61K38/00 , C07K14/7051 , C12Q1/6886 , G01N33/6893
摘要： The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.
摘要翻译：本发明提供了对癌症抗原（例如肾细胞癌抗原）具有抗原特异性的分离或纯化的T细胞受体（TCR），其中TCR以主要组织相容性复合体（MHC）为依赖性识别癌抗原。还提供了相关多肽，蛋白质，核酸，重组表达载体，分离的宿主细胞，细胞群，抗体或其抗原结合部分，以及药物组合物。本发明还提供了检测宿主中癌症存在的方法以及使用本发明的TCR或相关材料治疗或预防宿主中的癌症的方法。

36. 发明授权

US07811998B2 Novobiocin analogues as anticancer agents 有权
标题翻译：新生霉素类似物作为抗癌剂
公开(公告)号：US07811998B2
公开(公告)日：2010-10-12
申请号：US12571899
申请日：2009-10-01
申请人： Brian S. Blagg , Len Neckers , Xiao Ming Yu
发明人： Brian S. Blagg , Len Neckers , Xiao Ming Yu
IPC分类号： A01N43/04 , A61K31/70
CPC分类号： C07H17/075
摘要： Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.
摘要翻译：提供新生生物的类似物和衍生物，包括具有对酰胺侧链，香豆素环和糖部分的修饰的化合物。本发明的化合物可用作热休克蛋白90抑制剂，可用作抗癌和神经保护剂。

37. 发明授权

US07807472B2 Methods for separation and detection of ketosteroids and other carbonyl-containing compounds 有权
标题翻译：分离和检测酮类和其他含羰基化合物的方法
公开(公告)号：US07807472B2
公开(公告)日：2010-10-05
申请号：US10511409
申请日：2003-04-15
申请人： Xia Xu , Regina G. Ziegler , David J. Waterhouse , Joseph E. Saavedra , Larry K. Keefer
发明人： Xia Xu , Regina G. Ziegler , David J. Waterhouse , Joseph E. Saavedra , Larry K. Keefer
IPC分类号： G01N33/00 , G01N1/00
CPC分类号： G01N33/743 , G01N30/02 , G01N30/7233 , G01N30/7266 , Y10S436/817 , Y10T436/24 , B01D15/325
摘要： Methods for enhancing detection by mass spectroscopy (MS) and/or chromatographic separability of carbonyl-containing compounds such as steroids are disclosed. Reaction of a carbonyl compound with a sulfonhydrazide compound provides a sulfonhydrazone with enhanced ionization efficiency during the electrospray ionization process. In a particularly disclosed embodiment, derivatization of catechol estrogens with p-toluenesulfonhydrazide enhances both detection by atmospheric pressure ionization-MS (API-MS), such as electron spray ionization-MS (ESI-MS) and separation by liquid chromatography (such as HPLC) under reverse phase conditions. In yet other embodiments, the sulfonhydrazone is further reacted with a sulfonyl halide under alkaline conditions to derivatize hydroxyl groups in the compound. Prior formation of the sulfonhydrazide derivative protects the carbonyl bond of the compound during subsequent alkaline reaction with the sulfonyl halide.
摘要翻译：公开了通过质谱（MS）检测和/或含羰基化合物如类固醇的色谱分离性的方法。羰基化合物与磺酰肼化合物的反应提供了在电喷雾电离过程期间具有增强的电离效率的磺酰腙。在特别公开的实施方案中，儿茶酚雌激素与对甲苯磺酰肼的衍生增强了通过大气压电离-MS（API-MS）的检测，例如电子喷雾离子化-MS（ESI-MS）和通过液相色谱法分离（例如HPLC ）在反相条件下。在其它实施方案中，磺酰腙在碱性条件下进一步与磺酰卤反应以衍生化合物中的羟基。磺酰肼衍生物的先前形成在与磺酰卤的随后碱性反应期间保护化合物的羰基键。

38. 发明授权

US07803565B1 Use of lymphocytes to measure anthrax lethal toxin activity 有权
标题翻译：使用淋巴细胞测量炭疽致死毒素活性
公开(公告)号：US07803565B1
公开(公告)日：2010-09-28
申请号：US11399003
申请日：2006-04-05
申请人： David M. Frucht , Hui Fang
发明人： David M. Frucht , Hui Fang
IPC分类号： G01N33/00 , G01N33/53 , G01N33/569 , G01N33/573 , C12N5/07 , C12N5/16
CPC分类号： G01N33/5047 , C12Q1/18 , G01N33/6863 , G01N2333/32
摘要： It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4+ T-cell can be used to determine an amount of lymphocyte-associated anthrax lethal toxin activity present. Methods of using isolated lymphocytes to identify anthrax therapeutic agents and to determine the efficacy of a potential anthrax therapeutic are disclosed. Methods are also provided for diagnosing and treating anthrax infections.
摘要翻译：本文公开了分离的淋巴细胞，例如人B细胞和CD4 + T细胞可用于确定存在的淋巴细胞相关的炭疽致死毒素活性的量。公开了使用分离的淋巴细胞来识别炭疽治疗剂并确定潜在的炭疽治疗剂的功效的方法。还提供了诊断和治疗炭疽感染的方法。

39. 发明授权

US07777019B2 Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells 有权
标题翻译：突变的抗CD22抗体对表达CD22的白血病细胞的亲和力增加
公开(公告)号：US07777019B2
公开(公告)日：2010-08-17
申请号：US12030828
申请日：2008-02-13
申请人： Ira Pastan , Giuliana Salvatore , Richard Beers , Robert J. Kreitman
发明人： Ira Pastan , Giuliana Salvatore , Richard Beers , Robert J. Kreitman
IPC分类号： C07H21/04 , A61K39/395 , C07K16/00
CPC分类号： C07K16/2803 , A61K47/6829 , A61K47/6849 , A61K47/6875 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/624
摘要： Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
摘要翻译：重组免疫毒素是由与细菌或植物毒素融合的抗体的Fv结构域组成的融合蛋白。 RFB4（Fv）-PE38是靶向在B细胞和B细胞恶性肿瘤上表达的CD22的免疫毒素。与RFB4相比，本发明提供了具有改善的结合B细胞和B细胞恶性肿瘤的CD22抗原的能力的抗体和抗体片段。用本发明的抗体和抗体片段制备的免疫毒素对表达CD22的癌细胞具有改善的细胞毒性。将这些抗体并入可用于药物的嵌合免疫毒素分子中的组合物和用于抑制白血病和淋巴瘤细胞生长和增殖的方法。

40. 发明授权

US07771715B2 Recombinant vector expressing multiple costimulatory molecules and uses thereof 有权
标题翻译：表达多种共刺激分子的重组载体及其用途
公开(公告)号：US07771715B2
公开(公告)日：2010-08-10
申请号：US11723666
申请日：2007-03-21
申请人： Jeffrey Schlom , James Hodge , Dennis Panicali
发明人： Jeffrey Schlom , James Hodge , Dennis Panicali
IPC分类号： A61K48/00 , C12N15/00
CPC分类号： C12N15/86 , A61K35/12 , A61K39/00 , A61K48/00 , A61K2039/57 , C07K14/70503 , C07K14/70525 , C07K14/70528 , C07K14/70532 , C12N2710/24043 , C12N2710/24143 , Y02A50/41 , Y02A50/412 , Y02A50/464 , Y02A50/478
摘要： The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+ and CD8+ T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced antigen-presenting functions.
摘要翻译：本发明是编码并表达至少三种或更多共刺激分子的重组载体。重组载体可另外含有编码一种或多种靶抗原或其免疫表位的基因。证明了这些共刺激分子对增强的T细胞活化的协同作用。使用含有编码三个共刺激分子的基因的重组载体的T细胞活化程度远远大于含有一个共刺激分子并且大于使用两个共刺激分子的重组载体构建体的总和。使用三重共刺激载体的结果在低水平的第一信号或低刺激剂与T细胞比率的条件下最显着。用分离的CD4 +和CD8 + T细胞观察到这种现象。本发明的重组载体可用作抗癌和致病微生物的免疫原和疫苗，以及提供宿主细胞，包括具有增强的抗原呈递功能的树突状细胞和脾细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式